◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksC › CELC

Celcuity LLC (CELC) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-23

Celcuity LLC (CELC) operates in the BIOTECHNOLOGY industry and is headquartered in Minneapolis, United States with about 155 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, CELC reported $0M in revenue and ($177M) in net income.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

Interactive charts & full statements →

CELC Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Total Revenue$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M$0M
Gross Margin %-108.4%
Operating Income (EBIT)($209M)($172M)($113M)($66M)($39M)($28M)($10M)($8M)($8M)($6M)($3M)($2M)
Operating Margin %-111813.0%
Net Income($226M)($177M)($112M)($64M)($40M)($30M)($9M)($7M)($7M)($6M)($3M)($2M)
Net Margin %-114962.3%
EBITDA($185M)($160M)($101M)($58M)($38M)($28M)($9M)($7M)($8M)($6M)($3M)($2M)
Earnings Per Share (EPS)$-4.36$-3.37$-2.83$-2.69$-2.62$-2.21$-0.92$-0.72$-0.74$-0.84$-0.49$-0.36
Shares Outstanding (M)55M53M39M24M15M13M10M10M10M7M7M6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CELC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$0M$0M$0M$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M$0M$0M
Gross Margin %-26.6%-29.0%
Operating Income (EBIT)($66M)($51M)($49M)($43M)($44M)($36M)($36M)($30M)
Operating Margin %-27824.0%-30022.2%
Net Income($79M)($53M)($51M)($44M)($45M)($37M)($37M)($30M)
Net Margin %-28444.2%-30205.9%
EBITDA($55M)($47M)($45M)($39M)($42M)($34M)($33M)($26M)
Earnings Per Share (EPS)$-1.44$-0.97$-0.97$-0.98$-1.04$-0.86$-0.85$-0.70
Shares Outstanding (M)55M54M53M45M44M43M43M43M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CELC Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Cash from Operations (CFO)($192M)($153M)($83M)($54M)($36M)($20M)($7M)($6M)($6M)($5M)($3M)($2M)
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$0M$0M$0M$1M$0M$0M$0M
Free Cash Flow (FCF)($192M)($154M)($84M)($54M)($36M)($20M)($7M)($6M)($7M)($5M)($3M)($2M)
FCF Margin %-99694.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CELC Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($55M)($55M)($36M)($45M)($36M)($36M)($28M)($21M)
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$0M$0M$0M
Free Cash Flow (FCF)($55M)($55M)($36M)($45M)($36M)($36M)($28M)($21M)
FCF Margin %-29164.3%-22922.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CELC Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Total Assets$828M$467M$245M$191M$176M$86M$13M$20M$26M$32M$6M$5M
Cash & Cash Equivalents$182M$166M$23M$31M$25M$84M$12M$19M$16M$3M$6M$5M
Total Liabilities$841M$366M$130M$51M$42M$17M$1M$1M$1M$1M$0M$0M
Total Debt (Short + Long-Term)$0M$322M$98M$37M$35M$15M$0M$0M$0M$0M$0M$0M
Total Shareholders' Equity($13M)$101M$116M$140M$134M$69M$12M$19M$25M$31M$6M$5M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CELC viewer.

Other Companies in BIOTECHNOLOGY

← CELAll “C” companiesCELEBRITY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.